Quantified immunohistochemistry demonstrates cellular level targets of an oral multikinase inhibitor in metastatic thyroid cancer

Evan R. Ransom, Jason M. Leibowitz, Cathy Ma, Kanchan Puttaswamy, Andrea Troxel, William Lee, Michael Feldman, Marcia S. Brose

Research output: Contribution to journalArticle


Objectives: To describe a new technique for assaying effects of antitumor therapeutics over time. Study Design: Tumor tissue samples were taken from a Phase II clinical trial. A method for quantification of immuno-histochemistry (IHC) was developed using a computer algorithm designed to measure staining levels spectrographically. Phospho- ERK was selected as the tumor marker for this demonstration. Results: Average nuclear DAB intensities were 846.972 (pre-treatment) and 229.249 (on-treatment). Staining intensity frequency distribution curves generated showed statistically distinct distributions, both confirming and quantifying the decreased presence of phospho-ERK in the on-treatment sample. Conclusions: A novel technique for quantification of IHC is presented. This process can be used to delineate specific cellularlevel responses to targeted anti-tumor therapeutics.

Original languageEnglish (US)
Pages (from-to)S47
Issue numberSUPPL. 3
StatePublished - Oct 1 2010
Externally publishedYes


ASJC Scopus subject areas

  • Otorhinolaryngology

Cite this